title: FDA approves Novartis's CDK4/6 inhibitor.
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors; D017277:Drug Approval; D004345:Drug Industry; D005260:Female; D006801:Humans; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D011687:Purines; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; C000589651:ribociclib